Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.10.2 (focal adhesion kinase)
 44,029 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Several options exist for the detection of chlamydial infection in a routine laboratory setting. Enzyme immuno assay (EIA) technology offers rapid turn around of results and is less technically demanding than chlamydial cell culture. In addition, recently introduced EIA confirmatory reagents have the potential to improve the accuracy of EIA detection. We have evaluated one such confirmatory reagent (Chlamydia Blocking Reagent, Abbott Laboratories) to determine the accuracy of the Chlamydiazyme EIA with special regard to interpretation of low absorbance values. An initial series of 192 male urethral specimens showed that use of a lowered cut off level (absorbance value 0.05) compared with that recommended by the manufacturer increased sensitivity of the EIA from 0.73 to 0.83, thus motivating studies on this interpretative modification. Of 1101 EIA reactive specimens, 65% were determined to be chlamydia positive by the Chlamydia Blocking Reagent. The proportion of female cervical specimens that did not confirm positive was elevated compared with male urethral specimens, 43% vs. 5.7% respectively. In samples yielding absorbance from the recommended cut off level to 0.05 (approximately 50% below), the corresponding figures were 78% and 14% respectively. In 85 selected EIA reactive samples, examination by a direct immunofluorescence staining assay (DFA) (MicroTrak, Syva Inc.) revealed elementary bodies in 85% of 67 blocking test positive and in 24% of 18 blocking test negative samples. The possibility that Gram-negative bacteria were responsible for unconfirmed EIA reactive specimens was investigated using bacterial suspensions. While EIA reactivity was noted with several strains for Gram-negative bacteria, both the blocking reagent and DFA correctly verified the absence of chlamydial antigen.(ABSTRACT TRUNCATED AT 250 WORDS)
Int J STD AIDS
PMID:Chlamydia trachomatis antigen detection by Chlamydiazyme combined with Chlamydia Blocking Reagent verification. 139 Oct 63

A multi-centre, randomized, open-label trial was conducted to evaluate the safety and efficacy of recombinant interferon (rIFN) alpha-2c versus rIFN gamma in patients with recurrent or persistent condylomata acuminata (CA). Thirty-three such patients were treated either with 6 micrograms rIFN alpha-2c or with 0.1 mg rIFN gamma (both equivalent to 2 x 10E6 IU), single dose, subcutaneously 3 times a week for 6 weeks. In case of no complete clearance at week 10, a second course of treatment with the other type of rIFN was given. There was no significant difference in the complete clearance proportions at week 10 between the two treatment groups (3/16 vs 6/17). No relapses occurred in these patients during the 16 weeks' follow-up. Further clearances during the follow-up resulted in a total complete clearance proportion of 14/33 at the end of study. The treatment was well tolerated. Repeated interferon therapy has its place in treating persistent or recurrent condylomas.
Int J STD AIDS
PMID:Clinical study with recombinant interferon gamma versus interferon alpha-2c in patients with condylomata acuminata. 139 Oct 62

Spinal cord toxoplasmosis occurs rarely in the acquired immunodeficiency syndrome (AIDS). It usually presents as a space occupying lesion which makes differentiation from a neoplasm difficult. As a result, only 2 of the 5 previously reported cases have been diagnosed antemortem. We have incorporated the clinical details from one further case to describe the clinical features of this condition. The clarification of this clinical entity may allow earlier diagnosis of this rare condition in the future.
Int J STD AIDS
PMID:Spinal cord toxoplasmosis in a patient with human immunodeficiency virus infection. 139 Oct 67


Int J STD AIDS
PMID:Pyogenic abscess caused by Mycobacterium kansasii in advanced AIDS. 139 Oct 65


Int J STD AIDS
PMID:Missed human immunodeficiency virus seroconversion. 139 Oct 66

A retrospective analysis of the results of bacteriological examination of all urine samples from adult HIV infected patients admitted to the City Hospital, Edinburgh during the year 1 April 1988 to 31 March 1989 was made to assess the usefulness of this investigation in HIV positive patients without clinical evidence of urinary tract infection.
Int J STD AIDS
PMID:Value of bacteriological screening of urine samples from HIV infected patients. 139 Oct 64

Serum samples taken at delivery from 27 syphilitic mothers in Mozambique, 16 with stillborn babies and 11 with healthy babies, were tested for the presence of IgM antibodies against T. pallidum by the solid-phase hemadsorption assay (SPHA). 14 of 16 serum samples from mothers with stillborn babies but only 1 of 11 samples from mothers with healthy babies were found positive by the SPHA test. Clinical signs indicative of syphilis are difficult to find in the Maputo area, as there were more than 40,000 annual births and only 5 obstetricians when the study was conducted. It is believed that the findings may indicate that those mothers who were serologically positive with the SPHA test had clinically active syphilis and that syphilis may have been the cause or a contributory factor in the death of 14 of the stillborn babies. The SPHA test was easy to perform and the authors recommend its adoption by laboratories with facilities to perform the TPHA test.
Int J STD AIDS
PMID:IgM-antibodies against T. pallidum detected in sera from mothers of stillborn babies in Mozambique by the solid-phase haemadsorption assay (SPHA). 139 Oct 61


Int J STD AIDS
PMID:Vulval neurofibromatosis masquerading as genital warts. 139 Oct 68


Int J STD AIDS
PMID:Regional trends in viral STDs. 139 Oct 69


Int J STD AIDS
PMID:Heterosexual HIV transmission. 139 Oct 70


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>